Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers
Completed
Boehringer Ingelheim
Phase 1
2004-01-01
Study to establish the bioequivalence of a new formulation of Asasantin ER compared to the
present commercially available Asasantin ER formulation (Aggrenox®)
The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs
primary unassisted patency in newly created arteriovenous grafts. This record previously
included information for both the GRAFT and FISTULA trials.
The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs
primary unassisted patency in newly created arteriovenous grafts. This record previously
included information for both the GRAFT and FISTULA trials.
The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs
primary unassisted patency in newly created arteriovenous grafts. This record previously
included information for both the GRAFT and FISTULA trials.
The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs
primary unassisted patency in newly created arteriovenous grafts. This record previously
included information for both the GRAFT and FISTULA trials.
The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs
primary unassisted patency in newly created arteriovenous grafts. This record previously
included information for both the GRAFT and FISTULA trials.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
